Literature DB >> 21293503

Hepatitis in 2010: the dawn of a new era in HCV therapy.

Sandra Ciesek1, Michael P Manns.   

Abstract

Although several antiviral treatments for HBV infection have recently reached the market, no direct acting antiviral drugs to treat infection with HCV have been licensed in the 20 years since its identification. Excitingly, recent publications herald several small revolutions in antiviral treatment of HCV that have considerable relevance for prospective HCV therapies.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21293503     DOI： 10.1038/nrgastro.2010.219

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  7 in total

1.  Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3.

Authors:  Harshna Patel; E Jenny Heathcote
Journal:  Gut       Date:  2010-10-21       Impact factor: 23.059

2.  Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.

Authors:  Catherine L Jopling; Minkyung Yi; Alissa M Lancaster; Stanley M Lemon; Peter Sarnow
Journal:  Science       Date:  2005-09-02       Impact factor: 47.728

3.  Telaprevir for previously treated chronic HCV infection.

Authors:  John G McHutchison; Michael P Manns; Andrew J Muir; Norah A Terrault; Ira M Jacobson; Nezam H Afdhal; E Jenny Heathcote; Stefan Zeuzem; Hendrik W Reesink; Jyotsna Garg; Mohammad Bsharat; Shelley George; Robert S Kauffman; Nathalie Adda; Adrian M Di Bisceglie
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

4.  Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Authors:  Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; David Pound; Mitchell N Davis; Joseph S Galati; Stuart C Gordon; Natarajan Ravendhran; Lorenzo Rossaro; Frank H Anderson; Ira M Jacobson; Raymond Rubin; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Eirum Chaudhri; Janice K Albrecht
Journal:  Lancet       Date:  2010-08-06       Impact factor: 79.321

5.  Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.

Authors:  Edward J Gane; Stuart K Roberts; Catherine A M Stedman; Peter W Angus; Brett Ritchie; Rob Elston; David Ipe; Peter N Morcos; Linda Baher; Isabel Najera; Tom Chu; Uri Lopatin; M Michelle Berrey; William Bradford; Mark Laughlin; Nancy S Shulman; Patrick F Smith
Journal:  Lancet       Date:  2010-10-14       Impact factor: 79.321

6.  Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.

Authors:  Robert E Lanford; Elisabeth S Hildebrandt-Eriksen; Andreas Petri; Robert Persson; Morten Lindow; Martin E Munk; Sakari Kauppinen; Henrik Ørum
Journal:  Science       Date:  2009-12-03       Impact factor: 47.728

Review 7.  The way forward in HCV treatment--finding the right path.

Authors:  Michael P Manns; Graham R Foster; Jürgen K Rockstroh; Stefan Zeuzem; Fabien Zoulim; Michael Houghton
Journal:  Nat Rev Drug Discov       Date:  2007-12       Impact factor: 84.694
  7 in total
  32 in total

Review 1.  Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.

Authors:  Li-Ping Chen; Jun Zhao; Yan Du; Yi-Fang Han; Tong Su; Hong-Wei Zhang; Guang-Wen Cao
Journal:  World J Virol       Date:  2012-12-12

2.  Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1.

Authors:  Leopold Kong; Erick Giang; Justin B Robbins; Robyn L Stanfield; Dennis R Burton; Ian A Wilson; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-23       Impact factor: 11.205

3.  Computational reconstruction of Bole1a, a representative synthetic hepatitis C virus subtype 1a genome.

Authors:  Supriya Munshaw; Justin R Bailey; Lin Liu; William O Osburn; Kelly P Burke; Andrea L Cox; Stuart C Ray
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

Review 4.  A new era in the treatment of chronic hepatitis C infection.

Authors:  Dinesh Jothimani; George M Chandy; Hari Conjeevaram
Journal:  Indian J Gastroenterol       Date:  2012-09-28

5.  IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection.

Authors:  Heiyoung Park; Elisavet Serti; Onyinyechi Eke; Brian Muchmore; Ludmila Prokunina-Olsson; Stefania Capone; Antonella Folgori; Barbara Rehermann
Journal:  Hepatology       Date:  2012-11-19       Impact factor: 17.425

6.  Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.

Authors:  Golo Ahlenstiel; Birgit Edlich; Leah J Hogdal; Yaron Rotman; Mazen Noureddin; Jordan J Feld; Lauren E Holz; Rachel H Titerence; T Jake Liang; Barbara Rehermann
Journal:  Gastroenterology       Date:  2011-07-07       Impact factor: 22.682

7.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Authors:  Ludmila Prokunina-Olsson; Brian Muchmore; Wei Tang; Ruth M Pfeiffer; Heiyoung Park; Harold Dickensheets; Dianna Hergott; Patricia Porter-Gill; Adam Mumy; Indu Kohaar; Sabrina Chen; Nathan Brand; McAnthony Tarway; Luyang Liu; Faruk Sheikh; Jacquie Astemborski; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Timothy R Morgan; David L Thomas; Barbara Rehermann; Raymond P Donnelly; Thomas R O'Brien
Journal:  Nat Genet       Date:  2013-01-06       Impact factor: 38.330

8.  Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion.

Authors:  Sukanya Raghuraman; Heiyoung Park; William O Osburn; Emily Winkelstein; Brian R Edlin; Barbara Rehermann
Journal:  J Infect Dis       Date:  2012-01-31       Impact factor: 5.226

9.  Systematic analysis of enhancer and critical cis-acting RNA elements in the protein-encoding region of the hepatitis C virus genome.

Authors:  Derrick Chu; Songyang Ren; Stacy Hu; Wei Gang Wang; Aparna Subramanian; Deisy Contreras; Vidhya Kanagavel; Eric Chung; Justine Ko; Ranjit Singh Amirtham Jacob Appadorai; Sanjeev Sinha; Ziba Jalali; David W Hardy; Samuel W French; Vaithilingaraja Arumugaswami
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

10.  A protocol for analyzing hepatitis C virus replication.

Authors:  Songyang Ren; Deisy Contreras; Vaithilingaraja Arumugaswami
Journal:  J Vis Exp       Date:  2014-06-26       Impact factor: 1.355
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.